References
- To K, Friedman AH. Cytomegalovirus retinitis. JAMA 1993: 262(23)3337
- Centrili HL, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with in- travitreal ganciclovir: long-term results. Ophthalmology 1989; 96(3): 367–74
- Pertel P, Hirschtick R, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992: 5(11): 1069–74
- Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993; 168(3): 557–63
- Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163(4): 716–9
- Anand R, Nightingale SD, Fish RH, et al. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol 1993: 111 (2): 223–7
- Diaz-Llopis M, Chipont E, Sanchez S, et al. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol 1992; 114(6): 742–7
- Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326(4): 213–20 [Erratum, N EnglJ Med 1992; 326(17): 1172]
- Fletcher CV, Collier AC, Rhame FS, et al. Foscarnet for suppression of human immunodeficiency virus replication. Antimicrob Agents Chemother 1994; 38(3): 604–7
- Deray G, Martinez F, Kadama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989; 9(4): 316–21